Subscribe to RSS
DOI: 10.1055/s-0044-1787542
Impact of the ARRIVE Trial in Nulliparous Individuals with Morbid Obesity: Interrupted Time Series Analysis
Funding None.Abstract
Objective We aimed to examine rates of induction of labor at 39 weeks and cesarean delivery before and after the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial stratified by body mass index (BMI; kg/m2) category.
Study Design This was a repeated cross-sectional analysis of publicly available U.S. birth certificate data from 2015 to 2021. We limited analyses to nulliparous individuals with a singleton pregnancy, cephalic presentation, without chronic hypertension, diabetes (gestational or pregestational), and fetal anomaly who delivered between 39 and 42 weeks' gestation. The pre-ARRIVE period spanned from August 2016 to July 2018 and the post-ARRIVE period spanned from January 2019 to December 2020. The dissemination period of the ARRIVE trial was from August 2018 to December 2018. Our co-primary outcomes were induction at 39 weeks and cesarean delivery. Our secondary outcomes were overall induction of labor and preeclampsia. We conducted an interrupted time series analysis after stratifying by prepregnancy BMI (<40 or ≥40). Negative binomial regression was used to calculate adjusted incident rate ratios with 95% confidence intervals.
Results Of 2,122,267 individuals that were included, 2,051,050 had BMI <40 and 71,217 had BMI ≥40. In individuals with BMI <40, the post-ARRIVE period compared to the pre-ARRIVE period was associated with an increased rate of induction of labor at 39 weeks, a decreased rate of cesarean delivery, and an increased rate of overall induction of labor. In individuals with BMI ≥40, the post-ARRIVE period compared to the pre-ARRIVE period was associated with an increased rate of induction of labor at 39 weeks, an increased rate of overall induction of labor and a decreased rate of preeclampsia; however, the decrease in the rate of cesarean delivery was not significant.
Conclusion An increase in induction of labor at 39 weeks' gestation in individuals with BMI ≥40 was not associated with a decrease in the cesarean delivery rate.
Key Points
-
The ARRIVE trial increased 39-week labor inductions in BMI <40 and ≥40.
-
BMI <40 had fewer cesareans; BMI ≥40 showed no significant decrease.
-
Offering labor induction is reasonable as cesarean rates didn't increase.
Keywords
cesarean delivery - induction of labor - interrupted time series - morbid obesity - preeclampsiaPublication History
Received: 27 March 2024
Accepted: 10 May 2024
Article published online:
10 June 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Grobman WA, Rice MM, Reddy UM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med 2018; 379 (06) 513-523
- 2 Souter V, Nethery E, Levy B, Mclean K, Sitcov K. Elective induction of labor in nulliparas: has the ARRIVE trial changed obstetric practices and outcomes?. Am J Obstet Gynecol 2022; 226 (01) S83-S84
- 3 Hersh AR, Skeith AE, Sargent JA, Caughey AB. Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: a cost-effectiveness analysis. Am J Obstet Gynecol 2019; 220 (06) 590.e1-590.e10
- 4 Einerson BD, Nelson RE, Sandoval G. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Cost of elective labor induction compared with expectant management in nulliparous women. Obstet Gynecol 2020; 136 (01) 19-25
- 5 Gilroy LC, Al-Kouatly HB, Minkoff HL, McLaren Jr RA. Changes in obstetrical practices and pregnancy outcomes following the ARRIVE trial. Am J Obstet Gynecol 2022; 226 (05) 716.e1-716.e12
- 6 Tita ATN, Lai Y, Bloom SL. et al. Timing of delivery and pregnancy outcomes among laboring nulliparous women. Am J Obstet Gynecol 2012; 206 (03) 239.e1-239.e8
- 7 CDC. National Center for Health Statistics. Prevalence of Obesity and Severe Obesity Among Adults. United States, 2017–2018. 2020 . Accessed May 17, 2024 at www.cdc.gov ; https://www.cdc.gov/nchs/products/databriefs/db360.htm
- 8 Arrowsmith S, Wray S, Quenby S. Maternal obesity and labour complications following induction of labour in prolonged pregnancy. BJOG 2011; 118 (05) 578-588
- 9 Hermann M, Le Ray C, Blondel B, Goffinet F, Zeitlin J. The risk of prelabor and intrapartum cesarean delivery among overweight and obese women: possible preventive actions. Am J Obstet Gynecol 2015; 212 (02) 241.e1-241.e9
- 10 Yao R, Ananth CV, Park BY, Pereira L, Plante LA. Perinatal Research Consortium. Obesity and the risk of stillbirth: a population-based cohort study. Am J Obstet Gynecol 2014; 210 (05) 457.e1-457.e9
- 11 Nohr EA, Bech BH, Davies MJ, Frydenberg M, Henriksen TB, Olsen J. Prepregnancy obesity and fetal death: a study within the Danish National Birth Cohort. Obstet Gynecol 2005; 106 (02) 250-259
- 12 Centers for Disease Control and Prevention. Attachment to the Facility Worksheet for the Live Birth Certificate for Multiple Births 2016. Accessed September 6, 2023 at: https://www.cdc.gov/nchs/data/dvs/multiple-births-worksheet-2016.pdf
- 13 User Guide to the 2021 Natality Public Use File. 2022 . Accessed September 6, 2023 at: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/UserGuide2021.pdf
- 14 Centers for Disease Control and Prevention. National Vital Statistics System Birth Data. Accessed September 6, 2023 at: https://www.cdc.gov/nchs/nvss/births.htm
- 15 Clinical Guidance for Integration of the Findings of The ARRIVE Trial. Labor induction versus expectant management in low-risk nulliparous women. Am J Obstet Gynecol 2018 . Accessed May 17, 2023 at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2018/08/clinical-guidance-for-integration-of-the-findings-of-the-arrive-trial
- 16 Society of Maternal-Fetal (SMFM) Publications Committee. Electronic address: pubs@smfm.org. SMFM Statement on Elective Induction of Labor in Low-Risk Nulliparous Women at Term: the ARRIVE Trial. Am J Obstet Gynecol 2019; 221 (01) B2-B4
- 17 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27 (04) 299-309
- 18 Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2016; 46: 348-355
- 19 Shumway RH. Time Series Analysis and Its Applications: With R Examples. Springer Science + Business Media; 2017
- 20 Nethery E, Levy B, McLean K, Sitcov K, Souter VL. Effects of the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) Trial on elective induction and obstetric outcomes in term nulliparous patients. Obstet Gynecol 2023; 142 (02) 242-250
- 21 Kawakita T, Iqbal SN, Huang CC, Reddy UM. Nonmedically indicated induction in morbidly obese women is not associated with an increased risk of cesarean delivery. Am J Obstet Gynecol 2017; 217 (04) 451.e1-451.e8
- 22 Weiss JL, Malone FD, Emig D. et al; FASTER Research Consortium. Obesity, obstetric complications and cesarean delivery rate–a population-based screening study. Am J Obstet Gynecol 2004; 190 (04) 1091-1097
- 23 Wood R, Freret TS, Clapp M, Little S. Rates of induction of labor at 39 weeks and cesarean delivery following publication of the ARRIVE Trial. JAMA Netw Open 2023; 6 (08) e2328274